Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

COLOFLOW: Laser Speckle Contrast Imaging Versus Near-infrared Fluorescence Imaging With Indocyanine Green (COLOFLOW)

17 luglio 2026 aggiornato da: Joost R. van der Vorst, MD, PhD, Leiden University Medical Center
COLOFLOW is a prospective observational study investigating whether Laser Speckle Contrast Imaging (LSCI), a dye-free and objective perfusion imaging technique, corresponds with the currently used subjective assessment of indocyanine green (ICG) fluorescence during colorectal surgery. In approximately 30 patients undergoing elective colon or rectal resection with primary anastomosis, both imaging modalities will be performed intraoperatively. The surgeons will base their clinical decisions solely on standard ICG fluorescence imaging, while LSCI measurements are collected for research purposes and do not influence treatment. Postoperatively, quantitative ICG parameters will be analysed and compared with LSCI perfusion maps to determine whether objective ICG analysis improves agreement with LSCI over subjective interpretation alone. In addition, the study will evaluate the feasibility of using the PerfusiX-IGS LSCI system during open colorectal surgery and describe postoperative outcomes, including anastomotic leakage. The ultimate goal is to contribute to more objective and standardized perfusion assessment during colorectal surgery

Panoramica dello studio

Descrizione dettagliata

Study Title: COLOFLOW: Quantified ICG Fluorescence versus Laser Speckle Contrast Imaging (LSCI) for Perfusion Assessment in Colorectal Surgery.

Background Anastomotic leakage is a serious complication after colorectal surgery, occurring in approximately 10-15% of patients and contributing substantially to postoperative morbidity and mortality. Surgeons increasingly use indocyanine green (ICG) fluorescence imaging to assess bowel perfusion during surgery, but interpretation remains largely subjective and the technique has limitations, including dye dependency and difficulties with repeated measurements. Laser Speckle Contrast Imaging (LSCI) is a dye-free, real-time imaging technique that provides objective perfusion maps and may overcome several of these limitations.

Aim The primary aim of the study is to determine how well subjective intraoperative ICG fluorescence assessment agrees with LSCI perfusion imaging when evaluating bowel perfusion at the planned anastomotic site during colorectal surgery.

Secondary aims are:

To evaluate the spatial agreement between postoperative quantitative ICG analysis and LSCI perfusion boundaries.

To assess the feasibility of using the PerfusiX-IGS LSCI system during open colorectal surgery.

To record clinical outcomes, including anastomotic leakage rates.

Study Design COLOFLOW is a prospective, single-centre, observational study conducted at the Leiden University Medical Centre (LUMC). No randomization, blinding, or intervention is performed. LSCI measurements are recorded for research purposes only and do not influence surgical decision-making.

Participants The study includes approximately 30 adult patients undergoing elective colon or rectal resection with creation of a primary anastomosis. This population corresponds to patients enrolled in the ongoing QUANTICOLON study.

Inclusion Criteria

Age ≥18 years. Elective colorectal resection with primary anastomosis. Ability to provide informed consent.

Exclusion Criteria

Palliative surgery. Poor intraoperative visualization. Conditions that substantially interfere with perfusion assessment.

Methods

During surgery:

The surgeon identifies the planned bowel transection site under white light. The bowel is exteriorized for imaging. The PerfusiX-IGS LSCI system records a perfusion map. Standard-of-care ICG fluorescence imaging is then performed and interpreted subjectively by the surgeon.

After surgery, ICG recordings are quantitatively analysed using dedicated software to derive perfusion parameters such as:

Time to fluorescence onset (T0) Time to peak intensity (Tmax) Maximum intensity (Imax) Maximum normalized slope Outflow area-under-the-curve measurements

A custom Python-based analysis is used to compare the location of perfusion boundaries identified by both imaging techniques.

Outcomes Primary Endpoint

Agreement between subjective ICG interpretation and LSCI perfusion mapping, assessed by:

Categorical agreement (adequate vs. inadequate perfusion). Spatial agreement between perfusion boundaries identified by both modalities.

Secondary Endpoints

Distance between quantitative ICG and LSCI perfusion boundaries. Feasibility and usability of the PerfusiX-IGS system. Success rate of obtaining calibrated image documentation. Thirty-day postoperative outcomes, including complications and anastomotic leakage.

Statistical Analysis Categorical agreement will be evaluated using Cohen's kappa coefficient, while spatial agreement will be assessed with Bland-Altman analysis. Secondary analyses will explore whether quantitative ICG measurements provide better agreement with LSCI than subjective assessment alone.

Ethical Considerations The study is classified as non-WMO (non-Medical Research Involving Human Subjects Act) because it introduces no intervention beyond standard care. LSCI is non-contact, non-invasive, and does not influence treatment decisions. Risks to participants are minimal and primarily related to the storage and handling of anonymized imaging data.

Conclusion COLOFLOW investigates whether objective, dye-free LSCI can serve as a reliable reference method for bowel perfusion assessment during colorectal surgery and whether postoperative quantitative analysis of ICG fluorescence can improve upon the current subjective interpretation of ICG imaging. The study aims to support the development of more standardized and objective perfusion assessment strategies that may ultimately help reduce anastomotic leakage.

Tipo di studio

Osservativo

Iscrizione (Stimato)

30

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The population for this study consists of adult patients undergoing elective colon or rectal resection with the creation of a primary anastomosis

Descrizione

Inclusion Criteria:

  • Adults ≥18 years.
  • Undergoing elective colon resection with primary anastomosis.
  • Able to provide consent for postoperative analysis of intraoperative imaging

Exclusion Criteria:

  • Palliative surgery.
  • Factors that severely limit intraoperative visualization (per investigator judgement).

Conditions interfering with perfusion assessment (e.g., severe peripheral vascular compromise).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Agreement ICG vs LSCI
Lasso di tempo: Periprocedural and day 0 (day of surgery)
the agreement between subjective ICG fluorescence assessment and LSCI perfusion imaging at the planned anastomotic site during colorectal surgery. This agreement will be evaluated in two ways: (1) categorical agreement, determining whether both techniques classify perfusion as adequate or inadequate, and (2) spatial agreement, assessing how closely the perfusion boundary identified by the surgeon using ICG corresponds to the perfusion boundary detected by LSCI.
Periprocedural and day 0 (day of surgery)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Spatial Agreement
Lasso di tempo: From surgery untill 30 days follow up
Spatial distance (in millimetres) between the quantitative ICG perfusion boundary and the LSCI perfusion boundary
From surgery untill 30 days follow up
Feasibility Laser Speckle Device
Lasso di tempo: Peri-procedural (day 0)

the feasibility and usability of the PerfusiX-IGS LSCI system

Unit of Measure:

Successful acquisitions (%) Acquisition time (seconds) Technical failures (%)

Peri-procedural (day 0)
30-day postoperative clinical outcomes
Lasso di tempo: Day 0 untill 30-days post operatively
Clinical outcomes and the occurrence of anastomotic leakage. The proportion of patients experiencing any complication and the distribution of Clavien-Dindo grades will be recorded. Incidence of anastomotic leakage within 30 days after surgery, defined according to standard clinical and/or radiological criteria as applied in routine clinical practice. The proportion of patients diagnosed with anastomotic leakage will be recorded.
Day 0 untill 30-days post operatively

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 agosto 2026

Completamento primario (Stimato)

1 agosto 2027

Completamento dello studio (Stimato)

30 settembre 2027

Date di iscrizione allo studio

Primo inviato

14 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 luglio 2026

Primo Inserito (Effettivo)

22 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Cancro al colon

Prove cliniche su Laser Speckle Contrast Imaging

Sottoscrivi